Anticancer research最新文献_第10页

Improvement in Survival in Patients With Advanced Non-small Cell Lung Cancer. 改善晚期非小细胞肺癌患者的生存状况。

IF 1.6 4区医学

Anticancer research Pub Date : 2025-01-01 DOI: 10.21873/anticanres.17417

Keishi Yoshida, Kaoru Watanabe, Taku Nishimura, Hiroaki Ikushima, Sayaka Ohara, Hideyuki Takeshima, Toshio Sakatani, Kazuhiro Usui

{"title":"Improvement in Survival in Patients With Advanced Non-small Cell Lung Cancer.","authors":"Keishi Yoshida, Kaoru Watanabe, Taku Nishimura, Hiroaki Ikushima, Sayaka Ohara, Hideyuki Takeshima, Toshio Sakatani, Kazuhiro Usui","doi":"10.21873/anticanres.17417","DOIUrl":"10.21873/anticanres.17417","url":null,"abstract":"Background/aim: New treatment agents for advanced non-small cell lung carcinoma (NSCLC) have improved overall survival (OS) in the last 20 years. Nevertheless, treatment strategies for patients with NSCLC and pulmonary fibrosis have not yet been established. This study aimed to evaluate OS improvement in patients with stage IV NSCLC based on the underlying pulmonary diseases.Patients and methods: This study retrospectively reviewed 581 patients with stage IV NSCLC who received any antineoplastic agents. Patients were categorized into three groups based on their underlying pulmonary conditions: normal lungs, emphysema, and fibrosis. Additionally, patients were divided into four periods: A (2002-2006), B (2007-2011), C (2012-2016), and D (2017-2021). OS of patients with each underlying pulmonary disease was compared across the different periods and treatment agents [cytotoxic agents (CYs) only, molecular-targeted tyrosine kinase inhibitors (TKIs), and immune checkpoint inhibitors (ICIs)].Results: Emphysema and fibrosis were identified in 205 (35.3%) and 54 (9.3%) patients, respectively. Over the last two decades, the OS (months) of all patients improved (p<0.001), including patients with normal lungs (p=0.004) and patients with emphysema (p<0.001), but with no significant improvement in fibrosis (p=0.605). TKI and ICI improved OS in patients with normal lungs (p<0.001) and emphysema (p<0.001), but had no significant impact on OS in patients with fibrosis (p=0.502).Conclusion: Patients with advanced NSCLC have improved prognoses in the last 20 years except for patients with pulmonary fibrosis. To improve the prognosis of patients with lung cancer and pulmonary fibrosis, new strategies and treatments should be developed.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 1","pages":"295-305"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment Outcomes of Tyrosine Kinase Inhibitors and Durvalumab Plus Tremelimumab After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma. 酪氨酸激酶抑制剂和Durvalumab加Tremelimumab在Atezolizumab加Bevacizumab治疗肝细胞癌后的治疗效果。

IF 1.6 4区医学

Anticancer research Pub Date : 2025-01-01 DOI: 10.21873/anticanres.17412

Nobuaki Ishihara, Shohei Komatsu, Yoshihiko Yano, Yoshimi Fujishima, Jun Ishida, Masahiro Kido, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Toshihiko Yoshida, Kentaro Tai, Keisuke Arai, Hiroaki Yanagimoto, Hirochika Toyama, Takanori Matsuura, Toshifumi Tada, Yuzo Kodama, Takumi Fukumoto

{"title":"Treatment Outcomes of Tyrosine Kinase Inhibitors and Durvalumab Plus Tremelimumab After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.","authors":"Nobuaki Ishihara, Shohei Komatsu, Yoshihiko Yano, Yoshimi Fujishima, Jun Ishida, Masahiro Kido, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Toshihiko Yoshida, Kentaro Tai, Keisuke Arai, Hiroaki Yanagimoto, Hirochika Toyama, Takanori Matsuura, Toshifumi Tada, Yuzo Kodama, Takumi Fukumoto","doi":"10.21873/anticanres.17412","DOIUrl":"10.21873/anticanres.17412","url":null,"abstract":"Background/aim: Atezolizumab plus bevacizumab (AteBev) is widely used as a first-line treatment for advanced hepatocellular carcinoma (HCC). However, evidence regarding the optimal drug sequence following AteBev treatment is limited. This study aimed to compare the treatment outcomes between tyrosine kinase inhibitors (TKIs) and durvalumab plus tremelimumab (DurTre) following AteBev treatment.Patients and methods: Overall, 134 consecutive patients who received AteBev for advanced HCC were enrolled in this study. Treatment outcomes were retrospectively compared between TKIs (AteBev→TKI group) and DurTre (AteBev→DurTre group).Results: The AteBev→TKI and Ate→DurTre groups included 46 and 7 patients, respectively. The AteBev→TKI group had significantly longer median progression-free survival after second-line treatment (3.6 vs. 0.94 months, p<0.001). The disease control rate was significantly higher in the AteBev→TKI group (p=0.020). The serum alpha-fetoprotein levels significantly decreased at one month in the AteBev→TKI group (0.909 vs. 1.435, p=0.035), whereas the albumin-bilirubin score significantly decreased at one month in the AteBev→TKI group (0.875 vs. 0.952, p=0.017). Each group reported no new unmanageable adverse events.Conclusion: TKIs may be a more optimal drug sequence than DurTre after AteBev treatment from an oncological perspective. TKIs following AteBev treatment require careful monitoring for deteriorating liver function.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 1","pages":"251-260"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

EGFR Exon 19 Insertions: Do Patients Respond to Tyrosine Kinase Inhibitor Treatment? EGFR外显子19插入：患者对酪氨酸激酶抑制剂治疗有反应吗？

IF 1.6 4区医学

Anticancer research Pub Date : 2025-01-01 DOI: 10.21873/anticanres.17421

Giuseppina Improta, Giulia Vita, Alfredo Tartarone, Giovanni Calice, Ludmila Carmen Omer, Angela Zupa

{"title":"EGFR Exon 19 Insertions: Do Patients Respond to Tyrosine Kinase Inhibitor Treatment?","authors":"Giuseppina Improta, Giulia Vita, Alfredo Tartarone, Giovanni Calice, Ludmila Carmen Omer, Angela Zupa","doi":"10.21873/anticanres.17421","DOIUrl":"10.21873/anticanres.17421","url":null,"abstract":"Background/aim: Epidermal growth factor receptor (EGFR) exon 19 insertions are very rare mutations and their response to tyrosine kinase inhibitors (TKIs) is uncertain. We report our experience concerning two patients, along with a literature review.Patients and methods: A total of 1,046 non-small-cell lung cancer tumor tissue samples were screened for EGFR mutations, using direct sequencing or next-generation sequencing. Two patients presented the same insertion of 18 nucleotides in EGFR exon 19 and were treated with afatinib.Results: Both patients responded to afatinib, showing a stable disease (SD) and a progression-free survival (PFS) of 6 and 10 months along with an overall survival (OS) of 17 and 19 months, respectively. A review of the literature data concerning clinical responsiveness to different generations of TKIs in patients with EGFR exon 19 insertions, including data of our two patients (n=28), showed a response rate of 64% and disease control rate of 92%. The calculated median PFS for the 28 cases, independently of the TKIs administered, was 9 months; median OS (n=15) was 13 months. Median PFS for patients receiving gefitinib and erlotinib was 9 months and 12.5 months, respectively, consistent with the median PFS observed in patients with \"classical\" EGFR mutations, treated with these agents.Conclusion: Patients with EGFR insertions in exon 19 have demonstrated sensitivity to treatment with EGFR TKIs, suggesting that patients carrying these mutations should be treated with these inhibitors.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 1","pages":"335-340"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Vascular Pain and Nurse Burden in Peripheral Administration of Fosaprepitant/Fosnetupitant: A Prospective Observational Study. 一项前瞻性观察研究：外周给药氟沙吡坦/氟沙吡坦的血管疼痛和护理负担。

IF 1.6 4区医学

Anticancer research Pub Date : 2025-01-01 DOI: 10.21873/anticanres.17415

Yuko Kubota, Shiro Hatakeyama, Shuhei Suzuki, Hiroki Sawada, Yuko Sato, Takashi Yoshioka, Chika Ozawa

{"title":"Vascular Pain and Nurse Burden in Peripheral Administration of Fosaprepitant/Fosnetupitant: A Prospective Observational Study.","authors":"Yuko Kubota, Shiro Hatakeyama, Shuhei Suzuki, Hiroki Sawada, Yuko Sato, Takashi Yoshioka, Chika Ozawa","doi":"10.21873/anticanres.17415","DOIUrl":"10.21873/anticanres.17415","url":null,"abstract":"Background/aim: Vascular pain associated with NK1 receptor antagonists, particularly fosaprepitant, remains a significant challenge in cancer chemotherapy. The present study investigated the incidence of vascular pain with the administration of fosaprepitant and fosnetupitant and assessed the psychological burden on nurses performing venipuncture.Patients and methods: We conducted a prospective observational study involving 115 cancer patients receiving NK1 receptor antagonists via peripheral venous catheters. Vascular pain was evaluated using a numerical rating scale. Nurses' psychological burden was assessed through questionnaires and a qualitative analysis.Results: Vascular pain occurred in 19% of 304 venipunctures, and its incidence was significantly lower with fosnetupitant (3.1%) than with fosaprepitant (22.9%) (p<0.01). Switching from fosaprepitant to fosnetupitant reduced pain in all cases. Nurses experienced psychological burden in 97% of venipunctures, with severe distress (NRS ≥3) in 19% of cases. The qualitative analysis revealed that nurses' distress was affected by the vascular status, patient behavior, and concerns about drug administration.Conclusion: The incidence of vascular pain was lower with fosnetupitant than with fosaprepitant. Nurses experienced significant psychological burden during venipuncture, particularly when patients reported pain. These results suggest that fosnetupitant is a preferable option for reducing both patient discomfort and nurses' psychological burden in chemotherapy administration.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 1","pages":"277-285"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Improved Vitamin D Status Is Associated With Lower Incidence of Stillbirth. 提高维生素D水平与降低死产发生率有关。

IF 1.6 4区医学

Anticancer research Pub Date : 2025-01-01 DOI: 10.21873/anticanres.17411

Pelle G Lindqvist, Mika Gissler

{"title":"Improved Vitamin D Status Is Associated With Lower Incidence of Stillbirth.","authors":"Pelle G Lindqvist, Mika Gissler","doi":"10.21873/anticanres.17411","DOIUrl":"10.21873/anticanres.17411","url":null,"abstract":"Background/aim: Two retrospective studies of prospective cohorts showed doubled odds of birth asphyxia among women with low plasma vitamin D levels, and another study reported a four-fold increased risk of stillbirth. It was not known whether this was related to low sun exposure or to insufficient vitamin D per se. We aimed to assess if it was due to vitamin D status.Patients and methods: We analyzed the incidence of stillbirth in relation to national vitamin D status for all pregnancies in Finland and Sweden between 1994 and 2021 (n >4.3 million). Due to 50% of the population having low plasma vitamin D, Finland implemented an extensive vitamin D food fortification program in 2003 and doubled it in 2009 because of inadequate results. After 2009, 10% of Finnish women had low vitamin D levels. Stillbirth incidence was related to changes using cross-tabulation with 95% confidence intervals.Results: The stillborn incidence in Finland decreased from 4.1/1,000 (prior to 2003), to 3.4/1,000 (2004 to 2009), and to 2.8/1,000 after 2009. In the meantime, the Swedish stillbirth rate remained constant at 3.9/1,000 until 2018, when the Finnish food fortification plan was implemented in Sweden. Thereafter, the Swedish stillbirth incidence dropped to 3.2/1,000. The rate of intrahepatic cholestasis of pregnancy, another hypoxic pregnancy complication related to low plasma vitamin D levels, did not drop.Conclusion: In our large study of national vitamin D food fortification, improved vitamin D status was associated with a lower stillbirth rate in a dose-dependent manner.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 1","pages":"243-250"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preoperative High FIB-4 Index and NFS Scores Predict a Reduced Incidence of Metachronous Liver Metastasis Following Pancreaticoduodenectomy. 术前高FIB-4指数和NFS评分可预测胰十二指肠切除术后并发肝转移的发生率降低

IF 1.6 4区医学

Anticancer research Pub Date : 2025-01-01 DOI: 10.21873/anticanres.17413

Makoto Kawamoto, Yoshihiro Miyasaka, Hiroki Kaida, Masato Watanabe

{"title":"Preoperative High FIB-4 Index and NFS Scores Predict a Reduced Incidence of Metachronous Liver Metastasis Following Pancreaticoduodenectomy.","authors":"Makoto Kawamoto, Yoshihiro Miyasaka, Hiroki Kaida, Masato Watanabe","doi":"10.21873/anticanres.17413","DOIUrl":"10.21873/anticanres.17413","url":null,"abstract":"Background/aim: Liver metastasis (LM), pre-dominant in pancreatic cancer, is associated with a dismal 5-year survival rate. Reports on the presence of fatty liver and liver fibrosis in LM are conflicting. Although liver biopsy is the standard diagnostic method for fibrosis, alternative, less invasive scoring models have been explored. This study examined the relationship between preoperative liver conditions and metachronous LM in patients undergoing pancreaticoduodenectomy (PD) for pancreatic head cancer.Patients and methods: We conducted a retrospective study on patients with pancreatic head cancer who underwent surgery at a single University Hospital between 2008 and 2023. The primary focus was the effect of preoperative liver conditions on LM recurrence. We compared clinical variables between groups with LM recurrence and those with extrahepatic recurrence. Liver conditions were evaluated using the Fibrosis-4 (FIB-4) index, NAFLD-fibrosis score (NFS), aspartate aminotransferase (AST) to platelet (PLT) ratio index (APRI), and AST to alanine aminotransferase (ALT) ratio.Results: Fifty patients who underwent macroscopic curative surgery for pancreatic head cancer were analyzed. We observed LM and extrahepatic recurrences in 15 (30%) and 19 patients (38%), respectively. The extrahepatic recurrence group included two patients with viral hepatitis and one with alcoholic chronic pancreatitis. Preoperative factors and plain CT scans revealed significantly lower platelet levels and liver-to-spleen ratios, respectively, in the extrahepatic recurrence group. The FIB-4 index and NFS were significantly higher in the extrahepatic recurrence group than in the LM recurrence group.Conclusion: High preoperative FIB-4 Index and NFS scores could be potential predictors for reduced metachronous LM following PD for pancreatic head cancer.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 1","pages":"261-266"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

SLC7A11/xCT-mediated Cystine Uptake Regulates Intracellular Glutathione and Promotes Antioxidant Defense in Lymphatic Endothelial Cells. SLC7A11/xCT 介导的胱氨酸摄取调节细胞内谷胱甘肽并促进淋巴管内皮细胞的抗氧化防御。

IF 1.6 4区医学

Anticancer research Pub Date : 2025-01-01 DOI: 10.21873/anticanres.17393

Shiho Hashiguchi, Tomoko Tanaka, Ryosuke Mano, Seiji Kondo, Shohta Kodama

{"title":"SLC7A11/xCT-mediated Cystine Uptake Regulates Intracellular Glutathione and Promotes Antioxidant Defense in Lymphatic Endothelial Cells.","authors":"Shiho Hashiguchi, Tomoko Tanaka, Ryosuke Mano, Seiji Kondo, Shohta Kodama","doi":"10.21873/anticanres.17393","DOIUrl":"10.21873/anticanres.17393","url":null,"abstract":"Background/aim: In a tongue-submandibular lymph node (SLN) metastasis model, the cystine/glutamate transporter solute carrier family 7, member 11 (Slc7a11), also known as xCT, was found to increase in lymphatic endothelial cells (LECs) within SLNs prior to melanoma cell metastasis. However, the precise mechanism by which xCT influences LECs remains unclear. This study aimed to explore the role of xCT in primary cultured LECs.Materials and methods: To determine whether xCT is involved in cystine uptake and glutathione (GSH) synthesis in primary cultured LECs, cystine uptake and GSH assays were conducted. The antioxidant role of xCT was evaluated by measuring intracellular reactive oxygen species (ROS). Additionally, xCT expression was analyzed in human melanoma metastatic lymph nodes using immunohistochemical staining.Results: Slc7a11-knockdown LECs exhibited significantly reduced cystine uptake and intracellular GSH levels. ROS levels in Slc7a11-knockdown LECs were found to be increased compared to those in control LECs under H2O2-induced oxidative stress conditions. xCT stability is regulated by CD44v; therefore, we evaluated whether LYVE-1, a hyaluronic acid receptor in LECs, regulates xCT expression. LYVE-1 upregulates Slc7a11 mRNA expression, increasing GSH production in LECs. Furthermore, xCT expression was observed in LECs within human melanoma metastatic lymph nodes.Conclusion: xCT functions as a cystine transporter, contributing to increased GSH levels in lymphatic fluid in melanoma metastasis.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 1","pages":"65-71"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prediction and Monitoring of Adaptive Radiation Therapy Timing Using Two-dimensional X-ray Image-based Water Equivalent Thickness. 基于二维x射线图像的水等效厚度预测和监测适应性放射治疗时机。

IF 1.6 4区医学

Anticancer research Pub Date : 2025-01-01 DOI: 10.21873/anticanres.17427

Kouta Hirotaki, Shunsuke Moriya, Kento Tomizawa, Masashi Wakabayashi, Atsushi Motegi, Masashi Ito, Takeji Sakae

{"title":"Prediction and Monitoring of Adaptive Radiation Therapy Timing Using Two-dimensional X-ray Image-based Water Equivalent Thickness.","authors":"Kouta Hirotaki, Shunsuke Moriya, Kento Tomizawa, Masashi Wakabayashi, Atsushi Motegi, Masashi Ito, Takeji Sakae","doi":"10.21873/anticanres.17427","DOIUrl":"10.21873/anticanres.17427","url":null,"abstract":"Background/aim: This study aimed to predict the optimal timing for adaptive radiation therapy (ART) using two-dimensional X-ray image-based water equivalent thickness (2DWET).Patients and methods: Forty patients with oropharyngeal and hypopharyngeal cancer underwent Computed Tomography (CT) rescanning during treatment. An adaptive score (AS) was proposed to guide ART decisions based on changes in four dose indices: target coverage, spinal cord dose, parotid gland dose, and over-dose volume. Delivered dose distributions were reviewed by two head and neck radiation oncologists, with ART requirement evaluated using a four-point scale. Logistic regression determined the AS cutoff, while receiver operating characteristic analysis assessed 2DWET as a predictor of ART timing.Results: The AS strongly correlated with the oncologists' ART decisions (Pearson coefficients of 0.74 and 0.64). An AS cutoff of 7.5 optimally indicated ART requirement, matching oncologist decisions with sensitivities of 79.2% and 89.5%, and specificities of 87.5% and 81.0%, respectively. The 2DWET method identified the AS threshold of 7.5 with sensitivity and specificity of 63.2% and 81.0%.Conclusion: An AS of 7.5 was highly indicative of ART timing, aligning well with oncologists' decisions, and 2DWET demonstrated potential as a low-exposure, efficient tool for predicting ART timing in patients with oropharyngeal and hypopharyngeal cancers.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 1","pages":"387-397"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interaction of Vitamin D-BODIPY With Fat Cells and the Link to Obesity-associated Vitamin D Deficiency. 维生素D- bodipy与脂肪细胞的相互作用以及与肥胖相关的维生素D缺乏的联系。

IF 1.6 4区医学

Anticancer research Pub Date : 2025-01-01 DOI: 10.21873/anticanres.17392

Nazli Uçar, Jude T Deeney, R Taylor Pickering, Ting-Yu Fan, Ralf Loo, Peter M Mueller, Michael F Holick

{"title":"Interaction of Vitamin D-BODIPY With Fat Cells and the Link to Obesity-associated Vitamin D Deficiency.","authors":"Nazli Uçar, Jude T Deeney, R Taylor Pickering, Ting-Yu Fan, Ralf Loo, Peter M Mueller, Michael F Holick","doi":"10.21873/anticanres.17392","DOIUrl":"10.21873/anticanres.17392","url":null,"abstract":"Background/aim: Obese individuals often exhibit vitamin D deficiency, potentially due to sequestration in fat cells. Little is known about how vitamin D3 enters adipocytes and associates with the intracellular lipid droplet.Materials and methods: Newly differentiated human and mouse (3T3-L1) adipocytes and primary mouse adipocytes were treated with vitamin D3 covalently linked to green fluorescent BODIPY (VitD-B) or Green BODIPY (GB) as control. Cells were exposed to 10-100 nM concentrations for various lengths of time (1-48 h). Fluorescence microscopy assessed vitamin D distribution.Results: VitD-B demonstrated stable incorporation into adipocytes without enzymatic cleavage, as HPLC showed no free vitamin D3 after 72 h. Fluorescence microscopy showed GB uptake was rapid and persisted for 48 h. VitD-B uptake was more gradual compared to GB in the human and 3T3-L1 adipocytes. Primary mouse adipocytes exhibited similar uptake patterns, with VitD-B appearing within 1 h and fluorescence intensity increasing 1.2-fold at 8 h and 5.7-fold at 24 h. GB exhibited rapid fluorescence uptake in these same cells, 29-fold higher than VitD-B at 1 h. At 24 h, some VitD-B treated cells exhibited greater fluorescence intensity around the surface of the lipid droplets, which was not observed in GB. Isolated lipid droplets exhibited rapid and immediate uptake of both VitD-B and GB, indicating a strong affinity for these lipid structures. The time-dependent accumulation of vitamin D3 in human adipocytes mirrored VitD-B uptake.Conclusion: VitD-B is a reliable proxy for studying the dynamics of vitamin D3 uptake in adipocytes.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 1","pages":"55-63"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142908974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How to Predict Recurrence After Resection of Hepatocellular Carcinoma. 如何预测肝细胞癌切除术后复发。

IF 1.6 4区医学

Anticancer research Pub Date : 2025-01-01 DOI: 10.21873/anticanres.17404

Natalie Petruch, Louisa Bolm, Martina Nebbia, Shahrzad Arya, Marco Ventin, Motaz Qadan, Nahel Elias, Jannis Duhn, Dirk Rades, Leigh A Dageforde, Kenneth T Tanabe, Joseph Franses, Vikram Deshpande, Ulrich F Wellner, Tobias Keck, Onofrio Catalano, Cristina R Ferrone

{"title":"How to Predict Recurrence After Resection of Hepatocellular Carcinoma.","authors":"Natalie Petruch, Louisa Bolm, Martina Nebbia, Shahrzad Arya, Marco Ventin, Motaz Qadan, Nahel Elias, Jannis Duhn, Dirk Rades, Leigh A Dageforde, Kenneth T Tanabe, Joseph Franses, Vikram Deshpande, Ulrich F Wellner, Tobias Keck, Onofrio Catalano, Cristina R Ferrone","doi":"10.21873/anticanres.17404","DOIUrl":"10.21873/anticanres.17404","url":null,"abstract":"Background/aim: Predictors of recurrence following resection of hepatocellular carcinoma (HCC) are not fully established. This study investigated potential risk factors and prognostic scores for this situation.Patients and methods: In 297 patients undergoing resection of HCC between 2000 and 2021, risk scores and potential additional risk factors for intrahepatic and extrahepatic recurrence were assessed.Results: Median overall survival was 48.4 months, median time to recurrence 25.1 months. The Alpha-Fetoprotein (AFP)-score differentiated between low and high-risk groups (21.8 vs. 8.3 months, p=0.001), as did the Risk Estimation of Tumor Recurrence After Transplant (RETREAT)-score (16 vs. 9 months, p=0.004) and the Clinical Risk Score (CRS) (14.9 vs. 3.9 months, p=0.002). Advanced T-stage, multiple lesions, and vessel infiltration were significantly associated with any type of recurrence, advanced T-stage, and multiple lesions with intrahepatic recurrence.Conclusion: Predictors of recurrence following resection of HCC were identified. Prognostic scores traditionally used for patients receiving liver transplantation (AFP-score, RETREAT-score, CRS) were predictive also of recurrence after resection of HCC.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 1","pages":"189-199"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0